CASI Pharmaceuticals (CASIF) Revenue (2022 - 2025)

CASI Pharmaceuticals has reported Revenue for 4 years, with the latest figure at $7.2 million in Q4 2025.

• For the quarter ending Q4 2025, Revenue fell 45.93% year-over-year to $7.2 million; the trailing twelve-month figure through Dec 2025 stood at $20.7 million (down 27.42% YoY), and the FY2025 full-year result was $20.7 million, down 27.42% from the prior year.
• Revenue for Q4 2025 stood at $7.2 million, up from $3.1 million in the prior quarter.
• The five-year high for Revenue was $13.4 million in Q4 2024, with the low at $3.1 million in Q3 2025.
• Historically, Revenue has averaged $7.6 million across 4 years, with a median of $8.1 million in 2023.
• Annual changes were most pronounced in 2024 — Revenue surged 94.3% — and 2025, when it slumped 60.54%.
• CASI Pharmaceuticals' Revenue stood at $10.3 million in 2022, then plunged by 33.0% to $6.9 million in 2023, then surged by 94.3% to $13.4 million in 2024, then plunged by 45.93% to $7.2 million in 2025.
• The last three Revenue figures came in at $7.2 million (Q4 2025), $3.1 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.